Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Operations (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Cash from Operations data on record, last reported at 22271000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 9.17% year-over-year to 22271000.0; the TTM value through Dec 2025 reached 86099000.0, up 14.25%, while the annual FY2025 figure was 86099000.0, 14.25% up from the prior year.
  • Cash from Operations reached 22271000.0 in Q4 2025 per FHTX's latest filing, down from 18860000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 271534000.0 in Q1 2022 and bottomed at 32175000.0 in Q2 2023.
  • Average Cash from Operations over 5 years is 8062450.0, with a median of 23557500.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: tumbled 852.09% in 2021, then soared 1273.09% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 11882000.0 in 2021, then tumbled by 343.43% to 28924000.0 in 2022, then increased by 4.78% to 27541000.0 in 2023, then rose by 10.97% to 24519000.0 in 2024, then grew by 9.17% to 22271000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 22271000.0 in Q4 2025, 18860000.0 in Q3 2025, and 21000000.0 in Q2 2025.